Home/Bicara Therapeutics/James (Jim) P. Boylan
J(

James (Jim) P. Boylan

Chief Financial Officer

Bicara Therapeutics

Therapeutic Areas

Bicara Therapeutics Pipeline

DrugIndicationPhase
BCA101Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)Phase 1b/2